59 Views | 21 Downloads
Larry J. Anderson, larry.anderson@emory.edu
X.C., C.A.R., L.J.A. and E.J.A. proposed and designed the experiments. X.C., H-Y.S. and C.Y.L. performed ADCC experiments. X.C. and H-Y.S performed anti-influenza HA IgG ELISA, Western Blot, Flowcytometry and neuraminidase activity assay. J.T. performed HA-mediated membrane fusion assay. J.R.W. and S.G. generated monoclonal antibody E4.
This study was funded by Center of Excellence for Influenza Research and Surveillance (CEIRS) to L.J.A. We would like to thank Rebecca Kondor at CDC for providing us influenza strain information. We thank staff at UGA for kindly providing 2014-15 vaccinated specimens. Finally, we would like to thank all the participating volunteers for donating their specimens.
LJA has done paid consultancies on RSV vaccines for Bavarian Nordic, ClearPath Vaccines Company, Pfizer, and ADVI; his laboratory is currently receiving funding through Emory University from Pfizer for laboratory studies for RSV surveillance studies in adults, and Sciogen for animal studies of RSV vaccines; he is a co-inventor on several CDC patents on the RSV G protein and its CX3C chemokine motif relative to immune therapy and vaccine development; and is co-inventor on a patent filing for use of RSV platform VLPs with the F and G proteins for vaccines.
E.J.A has consulted for Pfizer, Sanofi Pasteur, Janssen, and Medscape, and his institution receives funds to conduct clinical research unrelated to this manuscript from MedImmune, Regeneron, PaxVax, Pfizer, GSK, Merck, Sanofi-Pasteur, Janssen, and Micron. He also serves on a safety monitoring board for Kentucky BioProcessing, Inc. and Sanofi Pasteur. His institution has also received funding from NIH to conduct clinical trials of Moderna and Janssen COVID-19 vaccines.
This study was funded through HHSN272201400004C (NIAID Centers of Excellence for Influenza Research and Surveillance, CEIRS)
The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or funding agency.